Использование иммунобиологических препаратов в терапии ревматоидного артрит
В данной статье рассматриваются вопросы оптимизации терапии ревматоидного артрита биологическими базисными противовоспалительными препаратами на основании определенных клинико-иммунологических предикторов. Приводится описание наиболее значимых предикторов, таких как индекс массы тела, курение, активность болезни, сопутствующая терапия и прогнозирование эффективности того или иного биологического препарата при наличии антител. Также приводятся данные о возможности прогнозирования ответа на определенный вид биологической терапии исходя из клинического варианта ревматоидного артрита.
1. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force [Guideline] / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 1. – P. 3–15. https://doi.org/10.1136/annrheumdis-2015-207524
2. Kiely, P. D. W. Biologic efficacy optimization – a step towards personalized medicine/ P. D. W. Kiely // Rheumatology. – 2015. – Vol. 55, N 5. – P. 780–788. https://doi.org/10.1093/rheumatology/kev356
3. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review / J. T. Joensuu [et al.] // PLoS ONE. – 2015. – Vol. 10, N 3. – P. e0119683. https://doi.org/10.1371/journal.pone.0119683
4. Firestein, G. S. The disease formerly known as rheumatoid arthritis / G. S. Firestein // Arthritis Res. Ther. – 2014. – Vol. 16, N 3. – Art. 114. https://doi.org/10.1186/ar4593
5. Клинический полиморфизм ревматоидного артрита в белорусской популяции пациентов / Е. В. Кундер [и др.] // Медицина. – 2017. – № 2. – С. 63–70.
6. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis / D. S. Gibson [et al.] // Expert Rev. Mol. Diagn. – 2014. – Vol. 15, N 2. – P. 219–234. https://doi.org/10.1586/14737159.2015.969244
7. Plant, D. Genetic and epigenetic predictors of responsiveness to treatment in RA / D. Plant, A. G. Wilson, A. Barton // Nat. Rev. Rheumatol. – 2014. – Vol. 10, N 6. – P. 329–337. https://doi.org/10.1038/nrrheum.2014.16
8. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics / G. Dennis Jr. [et al.] // Arthritis Res. Ther. – 2014. – Vol. 16, N 2. – P. R90. https://doi.org/10.1186/ar4555
9. Townsend, M. J. Molecular and cellular heterogeneity in the rheumatoid arthritis synovium: clinical correlates of synovitis / M. J. Townsend // Best Pract. Res. Clin. Rheumatol. – 2014. – Vol. 28, N 4. – P. 539–549. https://doi.org/10.1016/j.berh.2014.10.024
10. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register / K. L. Hyrich [et al.] // Rheumatology. – 2006. – Vol. 45, N 12. – P. 1558–1565. https://doi.org/10.1093/rheumatology/kel149
11. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA / J. L. Nam [et al.] // Ann. Rheumatic Dis. – 2010. – Vol. 69, N 6. – P. 976–986. https://doi.org/10.1136/ard.2009.126573
12. Daïen, C. I. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine / C. I. Daïen, J. Morel // Mediators Inflamm. – 2014. – Vol. 2014. – Art. ID 386148. https://doi.org/10.1155/2014/386148
13. Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study / S. M. Goodman [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 74, suppl. 2. – P. 138.2–139. https://doi.org/10.1136/annrheumdis-2015-eular.1973
14. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine / E. Gremese [et al.] // Arthritis Care Res. – 2012. – Vol. 65, N 1. – P. 94–100. https://doi.org/ 10.1002/acr.21768
15. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts / S. Saevarsdottir [et al.] // Arthritis Rheum. – 2010. – Vol. 63, N 1. – P. 26–36. https://doi.org/10.1002/art.27758
16. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register / L. E. Kristensen [et al.] // Rheumatology. – 2007. – Vol. 47, N 4. – P. 495–499. https://doi.org/10.1093/rheumatology/ken002
17. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register / M. M. Soliman [et al.] // J. Rheumatol. – 2011. – Vol. 39, N 2. – P. 240–246. https://doi.org/10.3899/jrheum.110610
18. Van Schouwenburg, P. A. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis / P. A. van Schouwenburg, T. Rispens, G. J. Wolbink // Nat. Rev. Rheumatol. – 2013. – Vol. 9, N 3. – P. 164–172. https://doi.org/10.1038/nrrheum.2013.4
19. Кундер, Е. В. Иммуногенность блокаторов фактора некроза опухоли альфа как причина резистентности к терапии / Е. В. Кундер // Лечеб. дело. – 2017. – № 2. – С. 55–64.
20. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis / J. D. Isaacs [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 72, N 3. – P. 329–336. https://doi.org/10.1136/ annrheumdis-2011-201117
21. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment / P. Lal [et al.] // Arthritis. Rheum. – 2011. – Vol. 63, N 12. – P. 3681–3691. https://doi.org/ 10.1002/art.30596
22. Personalized medicine for rheumatoid arthritis:serological and clinical patients profiles to optimize B and T cell targeted therapy / E. Feist [et al.] // Z. Rheumatol. – 2013. – Vol. 72, N 1. – P. 49–58. https://doi.org/ 10.1007/s00393-011-0885-4
23. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis / J. Sellam [et al.] // Arthritis Res. Ther. – 2016. – Vol. 18, N 1. – Р. 294. https://doi.org/ 10.1186 / s13075-016-1190-z
24. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-tnfa agent treatment in patients with rheumatoid arthritis: a meta-analysis / Q. Lv [et al.] // Plos ONE. – 2014. – Vol. 9, N 2. – P. e89442. https://doi.org/10.1371/journal.pone.0089442
25. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial / D. Porter [et al.] // Lancet. – 2016. – Vol. 388, N 10041. – P. 239–247. https://doi.org/10.1016/s0140-6736(16)00380-9
26. Singh, J. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review / J. A. Singh, S. Beg, M. A. Lopez-Olivo // J. Rheumatol. – 2011. – Vol. 38, N 1. – P. 10–20. https://doi.org/10.3899/jrheum.100717
27. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis / R. Alfonso-Cristancho [et al.] // Clin. Rheumatol. – 2016. – Vol. 36, N 1. – P. 25–34. https://doi.org/10.1007/ s10067-016-3435-2
28. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial / C. Gabay [et al.] // Lancet. – 2013. – Vol. 381, N 9877. – P. 1541–1550. https://doi.org/10.1016/s0140-6736(13)60250-0
29. Alam, J. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy / J. Alam, I. Jantan, S. N. A. Bukhari // Biomed. Pharmacother. – 2017. – Vol. 92. – P. 615–633. https://doi.org/10.1016/j.biopha.2017.05.055
30. Nishimoto, N. Interleukin 6: from bench to bedside / N. Nishimoto, T. Kishimoto // Nat. Clin. Pract. Rheumatol. – 2006. – Vol. 2, N 11. – P. 619–626. https://doi.org/10.1038/ncprheum0338
31. Effectiveness of biologic and non biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data / S. K. Paul [et al.] // Semin. Arthr. Rheum. – 2018. – Vol. 47, N 4. – P. 478–484. https://doi.org/10.1016/j.semarthrit.2017.08.001
32. Pandian, V. P. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies / V. P. Pandian, R. Srinivasan // Clin. Ophthalmol. – 2015. – Vol. 9. – P. 393–397. https://doi.org/10.2147/opth.s77210
33. Assmann, G. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers / G. Assmann, M. Pfreundschuh, J. Voswinkel // Clin. Exp. Rheumatol. – 2010. – Vol. 28, N 1, suppl. 57. – P. 81–83.
34. Chandra, P. A. Rituximab is useful in the treatment of Felty’s syndrome / P. A. Chandra, Y. Margulis, C. Schiff // Am. J. Ther. – 2008. – Vol. 15, N 4. – P. 321–322. https://doi.org/10.1097/mjt.0b013e318164bf32
35. Iaccheri, B. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis / B. Iaccheri [et al.] // Ocul. Immunol. Infamm. – 2010. – Vol. 18, N 3. – P. 223–225. https://doi.org/10.3109/09273941003739928
36. Coexistence of rheumatoid arthritis and ankylosing spondylitis / T. A. Barczyńska [et al.] // Reumatologia. – 2015. – Vol. 5. – P. 279–285. https://doi.org/10.5114/reum.2015.55832
37. Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis / R. Mazzucchelli [et al.] // Clin. Exp. Rheumatol. – 1992. – Vol. 10 (1). – P. 83–85.
38. Toussirot, E. Crohn’s disease associated with seropositive rheumatoid arthritis / E. Toussirot, D. Wendling // Clin. Exp. Rheumatol. – 1997. – Vol. 15, N 3. – P. 307–311.
39. Bogas, M. Erosive enteropathy in a patient with polyarthritis / M. Bogas, M. C. Afonso, D. Araújo // Acta Reumatol. Port. – 2006. – Vol. 31, N 4. – P. 349–354.
40. Ulcerative colitis and rheumatoid arthritis: a rare association--case report / V. A. Cruz [et al.] // Rev. Bras. Reumatol. – 2012. – Vol. 52, N 4. – P. 648–650.
41. Azevedo, V. F. Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria / V. F. Azevedo, P. G. Buiar // Rev. Bras. Reumatol. (En. ed.). – 2013. – Vol. 53, N 1. – P. 111–119. https://doi.org/10.1016/s2255-5021(13)70011-7
42. Association of HLA alleles and clinical features in patients with synovitis of recent onset / H. S. El-Gabalawy [et al.] // Arthritis Rheum. – 1999. – Vol. 42, N 8. – P. 1696–1705. https://doi.org/10.1002/1529-0131(199908)42:83.0.co;2-k
43. Jajić, Z. HLA B27 antigen and rheumatoid arthritis / Z. Jajić, I. Jajić // Acta Med. Iugosl. – 1991. – Vol. 45, N 3. – P. 195–202.
44. Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study / A. Mera-Varela [et al.] // PLoS ONE. – 2013. – Vol. 8, N 3. – P. e58616. https://doi.org/10.1371/journal.pone.0058616
45. HLA-B27 in French patients with rheumatoid arthritis / A. Saraux [et al.] // Scand. J. Rheumatol. – 1997. – Vol. 26, N 4. – P. 269–271. https://doi.org/10.3109/03009749709105315
46. Jurik, A. G. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27 / A. G. Jurik, A. de Carvalho, H. Graudal // RöFo – Fortschritte auf dem Gebiet der R. – 1987. – Vol. 147, N 7. – P. 14–20. https://doi.org/10.1055/s-2008-1048582